Skip to main content

03.11.2022 | Research

Prenatal Detection of Congenital Heart Disease: Importance of Fetal Echocardiography Following Normal Fetal Cardiac Screening

verfasst von: Nupur Makkar, Gary Satou, Greggory R. DeVore, Mark Sklansky

Erschienen in: Pediatric Cardiology

Einloggen, um Zugang zu erhalten

Abstract

Fetal echocardiography may be performed because of noncardiac indications (the pregnancy is identified as high risk for fetal cardiac disease), or because of fetal cardiac indications (abnormal fetal heart at the time of a screening ultrasound). Considering recent improvements in fetal cardiac screening over the past decade, the goal of this single institution study was to reconsider the importance of performing fetal echocardiography purely for screening (noncardiac) indications. We performed a retrospective analysis to review screening and fetal cardiac indications and fetal cardiac findings for fetal echocardiograms performed at UCLA between 2015 and 2019. Fetal heart disease was identified in 391 (15%) of 2592 pregnancies in this study. Among these 391 cases, 227 (58%) occurred in low-risk pregnancies (without screening indications). While 79% of the cases of fetal cardiac disease were referred with fetal cardiac indications, 21% of the cases were referred with exclusively screening indications. Fetal cardiac disease was discovered on fetal echocardiograms in 4% of pregnancies referred for exclusively screening indications, but the frequency of fetal cardiac disease following normal fetal cardiac screening has decreased from 6% in 2015 to 3% in 2019. In our population, we recommend continued referral for fetal echocardiography for pregnancies identified as high risk for CHD. However, as fetal cardiac screening continues to improve, referral for fetal echocardiography following normal fetal cardiac screening will have diminishing value and yield.
Literatur
3.
Zurück zum Zitat Khoshnood B, Lelong N, Houyel L, Thieulin AC, Jouannic JM, Magnier S, Delezoide AL, Magny JF, Rambaud C, Bonnet D, Goffinet F (2012) EPICARD Study Group. Prevalence, timing of diagnosis and mortality of newborns with congenital heart defects: a population-based study. Heart 98(22):1667–1673CrossRefPubMed Khoshnood B, Lelong N, Houyel L, Thieulin AC, Jouannic JM, Magnier S, Delezoide AL, Magny JF, Rambaud C, Bonnet D, Goffinet F (2012) EPICARD Study Group. Prevalence, timing of diagnosis and mortality of newborns with congenital heart defects: a population-based study. Heart 98(22):1667–1673CrossRefPubMed
4.
Zurück zum Zitat Mahle WT, Newburger JW, Matherne GP, Smith FC, Hoke TR, Koppel R, Gidding SS, Beekman RH, Grosse SD (2009) American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, and Interdisciplinary Council on Quality of Care and Outcomes Research; American Academy of Pediatrics Section on Cardiology and Cardiac Surgery, and Committee on Fetus and Newborn. Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the American Heart Association and American Academy of Pediatrics. Circulation 120(5):447–458. https://doi.org/10.1161/CIRCULATIONAHA.109.192576CrossRefPubMed Mahle WT, Newburger JW, Matherne GP, Smith FC, Hoke TR, Koppel R, Gidding SS, Beekman RH, Grosse SD (2009) American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, and Interdisciplinary Council on Quality of Care and Outcomes Research; American Academy of Pediatrics Section on Cardiology and Cardiac Surgery, and Committee on Fetus and Newborn. Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the American Heart Association and American Academy of Pediatrics. Circulation 120(5):447–458. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​109.​192576CrossRefPubMed
5.
7.
Zurück zum Zitat Bakker M, Bergman J, Krivov S, Amar E, Cocchi G, Cragan J, de Walle HEK, Gatt M, Groisman B, Liu S, Nembhard WN, Pierini A, Rissmann A, Chidambarathanu S, Sipek A, Szabova E, Tagliabue G, Tucker D, Mastroiacovo P, Botto LD (2019) Prenatal diagnosis and prevalence of critical congenital heart defects: an international retrospective cohort study. Br Med J. https://doi.org/10.1136/bmjopen-2018-028139CrossRef Bakker M, Bergman J, Krivov S, Amar E, Cocchi G, Cragan J, de Walle HEK, Gatt M, Groisman B, Liu S, Nembhard WN, Pierini A, Rissmann A, Chidambarathanu S, Sipek A, Szabova E, Tagliabue G, Tucker D, Mastroiacovo P, Botto LD (2019) Prenatal diagnosis and prevalence of critical congenital heart defects: an international retrospective cohort study. Br Med J. https://​doi.​org/​10.​1136/​bmjopen-2018-028139CrossRef
8.
Zurück zum Zitat Sklansky M, DeVore GR (2016) Fetal cardiac screening: what are we (and Our guidelines) doing wrong? J Ultrasound Med 35(4):679–681CrossRefPubMed Sklansky M, DeVore GR (2016) Fetal cardiac screening: what are we (and Our guidelines) doing wrong? J Ultrasound Med 35(4):679–681CrossRefPubMed
9.
Zurück zum Zitat Cardinal MP, Gagnon MH, Têtu C, Beauchamp FO, Roy LO, Noël C, Vaujois L, Cavallé-Garrido T, Bigras JL, Roy-Lacroix MÈ, Dallaire F (2022) Incremental detection of severe congenital heart disease by fetal echocardiography following a normal second trimester ultrasound scan in Québec. Canada Circ Cardiovasc Imaging 15(4):e013796. https://doi.org/10.1161/CIRCIMAGING.121.013796CrossRefPubMed Cardinal MP, Gagnon MH, Têtu C, Beauchamp FO, Roy LO, Noël C, Vaujois L, Cavallé-Garrido T, Bigras JL, Roy-Lacroix MÈ, Dallaire F (2022) Incremental detection of severe congenital heart disease by fetal echocardiography following a normal second trimester ultrasound scan in Québec. Canada Circ Cardiovasc Imaging 15(4):e013796. https://​doi.​org/​10.​1161/​CIRCIMAGING.​121.​013796CrossRefPubMed
10.
Zurück zum Zitat Cawyer CR, Kuper SG, Ausbeck E, Sinkey RG, Owen J (2019) The added value of screening fetal echocardiography after normal cardiac views on a detailed ultrasound. Prenatal Diag 39(12):1148–1154CrossRefPubMed Cawyer CR, Kuper SG, Ausbeck E, Sinkey RG, Owen J (2019) The added value of screening fetal echocardiography after normal cardiac views on a detailed ultrasound. Prenatal Diag 39(12):1148–1154CrossRefPubMed
11.
Zurück zum Zitat Wright L, Stauffer N, Samai C, Oster M (2014) Who should be referred? An evaluation of referral indications for fetal echocardiography in the detection of structural congenital heart disease. Pediatr Cardiol 35(6):928–933CrossRefPubMed Wright L, Stauffer N, Samai C, Oster M (2014) Who should be referred? An evaluation of referral indications for fetal echocardiography in the detection of structural congenital heart disease. Pediatr Cardiol 35(6):928–933CrossRefPubMed
Metadaten
Titel
Prenatal Detection of Congenital Heart Disease: Importance of Fetal Echocardiography Following Normal Fetal Cardiac Screening
verfasst von
Nupur Makkar
Gary Satou
Greggory R. DeVore
Mark Sklansky
Publikationsdatum
03.11.2022
Verlag
Springer US
Erschienen in
Pediatric Cardiology
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-022-03032-6

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.